Comparison

Emilumenib European Partner

Item no. HY-148676-100mg
Manufacturer MedChem Express
CASRN 2440018-29-9
Amount 100 mg
Quantity options 100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 96.22
Citations [1]Cycloalkane-1, 3-diamine derivatives, et al. Cycloalkane-1, 3-diamine derivatives. Patent. CN113164481A.|[2]Numata M, et al., A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023 Feb 25;23(1):36.
Smiles CN([C@H]1C[C@H](C[C@H]1O)NCC2=CC=C(C3=CC(OC)=C(N=N3)OC)C=C2)C4=C5C(SC(CC(F)(F)F)=C5)=NC=N4
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias DS-1594a,Menin-MLL inhibitor 26
Shipping Condition Cool pack
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Epigenetic Reader Domain
Shipping Temperature
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Molecular Weight
574.62
Product Description
Emilumenib (Menin-MLL inhibitor 26) is an orally active Menin-MLL inhibitor. Emilumenib also is an active reference. Emilumenib can inhibits cell growth. Emilumenib can be used for the research of leukemia[1].
Manufacturer - Research Area
Cancer
Solubility
DMSO: 41.67 mg/mL (ultrasonic; warming)
Manufacturer - Pathway
Epigenetics
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close